CoChat

Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review

Open access
Butt, Muhammad, Zaman, Muhammad, Ahmad, Abrar, Khan, Rahima, Mallhi, Tauqeer, Hasan, Mohammad, Khan, Yusra, Hafeez, Sara, Massoud, Ehab, Rahman, Md., Cavalu, Simona · 2022 · Genes
Cited by 210

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Over the past few decades, gene therapy has gained immense importance in medical research as a promising treatment strategy for diseases such as cancer, AIDS, Alzheimer’s disease, and many genetic disorders. When a gene needs to be delivered to a target cell inside the human body, it has to pass a large number of barriers through the extracellular and intracellular environment. This is why the delivery of naked genes and nucleic acids is highly unfavorable, and gene delivery requires suitable vectors that can carry the gene cargo to the target site and protect it from biological degradation. To date, medical research has come up with two types of gene delivery vectors, which are viral and nonviral vectors. The ability of viruses to protect transgenes from biological degradation and their capability to efficiently cross cellular barriers have allowed gene therapy research to develop new approaches utilizing viruses and their different genomes as vectors for gene delivery. Although viral vectors are very efficient, science has also come up with numerous nonviral systems based on cationic lipids, cationic polymers, and inorganic particles that provide sustainable gene expression without triggering unwanted inflammatory and immune reactions, and that are considered nontoxic. In this review, we discuss in detail the latest data available on all viral and nonviral vectors used in gene delivery. The mechanisms of viral and nonviral vector-based gene delivery are presented, and the advantages and disadvantages of all types of vectors are also given.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/genes13081370

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 115

  1. Hill, 2016, Overcoming gene-delivery hurdles: Physiological considerations for nonviral vectors, Trends Biotechnol., 34, 91, 10.1016/j.tibtech.2015.11.004 · DOI · Paper page
  2. Zhang, 2012, In vivo gene delivery by nonviral vectors: Overcoming hurdles?, Mol. Ther., 20, 1298, 10.1038/mt.2012.79 · DOI · Paper page
  3. Kotterman, 2015, Viral vectors for gene therapy: Translational and clinical outlook, Annu. Rev. Biomed. Eng., 17, 63, 10.1146/annurev-bioeng-071813-104938 · DOI · Paper page
  4. Lukashev, 2016, Viral vectors for gene therapy: Current state and clinical perspectives, Biochemistry, 81, 700
  5. Desfarges, S., and Ciuffi, A. (2012). Viral integration and consequences on host gene expression. Viruses: Essential Agents of Life, Springer. · DOI
  6. Crenshaw, B.J., Jones, L.B., Bell, C.R., Kumar, S., and Matthews, Q.L. (2019). Perspective on adenoviruses: Epidemiology, pathogenicity, and gene therapy. Biomedicines, 7. · DOI
  7. Giacca, M. (2010). Introduction to gene therapy. Gene Therapy, Springer. · DOI
  8. Tsai, 2000, Adenovirus-mediated transfer of regulable gene expression, Curr. Opin. Mol. Ther., 2, 515
  9. Lyons, 2006, Adenovirus type 5 interactions with human blood cells may compromise systemic delivery, Mol. Ther., 14, 118, 10.1016/j.ymthe.2006.01.003 · DOI
  10. Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80, 148, 10.1016/j.ymgme.2003.08.016 · DOI · Paper page
  11. Bandara, 2021, Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy, Cell Biosci., 11, 145, 10.1186/s13578-021-00662-w · DOI
  12. Cao, 2020, A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations, Eur. Respir. J., 56, 2000205, 10.1183/13993003.00205-2020 · DOI
  13. Ricobaraza, A., Gonzalez-Aparicio, M., Mora-Jimenez, L., Lumbreras, S., and Hernandez-Alcoceba, R. (2020). High-capacity adenoviral vectors: Expanding the scope of gene therapy. Int. J. Mol. Sci., 21. · DOI
  14. Singh, 2019, Adenoviral vector-based vaccines and gene therapies: Current status and future prospects, Adenoviruses, 4, 53
  15. Chandler, 2016, Gene therapy for metabolic diseases, Transl. Sci. Rare Dis., 1, 73
  16. Pereboev, 2004, Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule, Mol. Ther., 9, 712, 10.1016/j.ymthe.2004.02.006 · DOI
  17. Rivera, 2007, Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer, Int. J. Cancer, 120, 935, 10.1002/ijc.22338 · DOI
  18. Matthews, 2006, Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion, Mol. Imaging, 5, 7290.2006.00029, 10.2310/7290.2006.00029 · DOI
  19. Tang, 2008, Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX, Virology, 377, 391, 10.1016/j.virol.2008.04.023 · DOI
  20. Cattoglio, 2010, High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors, Blood J. Am. Soc. Hematol., 116, 5507
  21. Vogt, 2012, Retroviral oncogenes: A historical primer, Nat. Rev. Cancer, 12, 639, 10.1038/nrc3320 · DOI · Paper page
  22. Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat. Biotechnol., 24, 687, 10.1038/nbt1216 · DOI · Paper page
  23. Ramezani, 2002, Overview of the HIV-1 lentiviral vector system, Curr. Protoc. Mol. Biol., 60, 16.21. 11
  24. Collins, 2017, Viral vector biosafety in laboratory animal research, Comp. Med., 67, 215
  25. Romano, 2012, Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: A critical issue for the field of gene therapy, Int. Sch. Res. Not., 2012, 616310
  26. David, 2017, Viral vectors: The road to reducing genotoxicity, Toxicol. Sci., 155, 315, 10.1093/toxsci/kfw220 · DOI · Paper page
  27. Montes, 2005, Viral vectors in gene therapy. Advantages of the adenoassociated vectors, Rev. Gastroenterol. Mex., 70, 192
  28. Conrad, S.J., and Liu, J. (2019). Poxviruses as gene therapy vectors: Generating Poxviral vectors expressing therapeutic transgenes. Viral Vectors for Gene Therapy, Springer. · DOI
  29. Mell, 2017, Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma, Clin. Cancer Res., 23, 5696, 10.1158/1078-0432.CCR-16-3232 · DOI
  30. Ono, C., Okamoto, T., Abe, T., and Matsuura, Y. (2018). Baculovirus as a tool for gene delivery and gene therapy. Viruses, 10. · DOI · Paper page
  31. Weklak, D., Pembaur, D., Koukou, G., Jönsson, F., Hagedorn, C., and Kreppel, F. (2021). Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector–Host Interactions. Viruses, 13. · DOI
  32. Liu, 2018, Current Status of Nonviral Vectors for Gene Therapy in China, Hum. Gene Ther., 29, 110, 10.1089/hum.2017.226 · DOI
  33. Hidai, C., and Kitano, H. (2018). Nonviral gene therapy for cancer: A review. Diseases, 6. · DOI
  34. Jones, 2015, Contemporary approaches for nonviral gene therapy, Discov. Med., 19, 447
  35. Guy, 2005, Physical methods for gene transfer: Improving the kinetics of gene delivery into cells, Adv. Drug Deliv. Rev., 57, 733, 10.1016/j.addr.2004.12.007 · DOI · Paper page
  36. Jinturkar, K.A., Rathi, M.N., and Misra, A. (2011). Gene delivery using physical methods. Challenges in Delivery of Therapeutic Genomics and Proteomics, Elsevier. · DOI
  37. Hosokawa, 2009, Gene delivery process in a single animal cell after femtosecond laser microinjection, Appl. Surf. Sci., 255, 9880, 10.1016/j.apsusc.2009.04.111 · DOI
  38. King, R. (2004). Gene delivery to mammalian cells by microinjection. Gene Delivery to Mammalian Cells, Springer.
  39. Lui, 2001, Systemic production of IL-12 by naked DNA mediated gene transfer: Toxicity and attenuation of transgene expression in vivo, J. Gene Med., 3, 384, 10.1002/jgm.201 · doi:10.1002/jgm.201
  40. Springer, 2001, Gene delivery to muscle, Curr. Protoc. Hum. Genet., 31, 13.14. 11
  41. Wendell, D.M., Hemond, B.D., Hogan, N.C., Taberner, A.J., and Hunter, I.W. (September, January 30). The effect of jet parameters on jet injection. Proceedings of the 2006 International Conference of the IEEE Engineering in Medicine and Biology Society, New York, NY, USA. · DOI
  42. Fargnoli, 2014, A needleless liquid jet injection delivery method for cardiac gene therapy: A comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression, J. Cardiovasc. Transl. Res., 7, 756, 10.1007/s12265-014-9593-1 · DOI
  43. Lysakowski, 2003, A needle-free jet-injection system with lidocaine for peripheral intravenous cannula insertion: A randomized controlled trial with cost-effectiveness analysis, Anesth. Analg., 96, 215
  44. Chuang, 2003, Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA, J. Urol., 170, 2044, 10.1097/01.ju.0000092945.76827.47 · doi:10.1097/01.ju.0000092945.76827.47
  45. Dutta, 2021, Nonviral gene therapy: Technology and application, Res. J. Sci. Technol., 13, 13, 10.5958/2349-2988.2021.00003.6 · doi:10.5958/2349-2988.2021.00003.6
  46. Neumann, 1982, Gene transfer into mouse lyoma cells by electroporation in high electric fields, EMBO J., 1, 841, 10.1002/j.1460-2075.1982.tb01257.x · DOI · Paper page
  47. Titomirov, 1991, In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA, Biochim. Et Biophys. Acta (BBA)-Gene Struct. Expr., 1088, 131, 10.1016/0167-4781(91)90162-F · DOI · Paper page
  48. Heller, 2006, In vivo electroporation for gene therapy, Hum. Gene Ther., 17, 890, 10.1089/hum.2006.17.890 · DOI · Paper page
  49. Young, 2015, Electroporation-mediated gene delivery, Adv. Genet., 89, 49, 10.1016/bs.adgen.2014.10.003 · DOI · Paper page
  50. Lambricht, 2016, Clinical potential of electroporation for gene therapy and DNA vaccine delivery, Expert Opin. Drug Deliv., 13, 295, 10.1517/17425247.2016.1121990 · DOI · Paper page
  51. Aslan, 2006, Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration, Tissue Eng., 12, 877, 10.1089/ten.2006.12.877 · DOI
  52. Delalande, 2012, Ultrasound and microbubble-assisted gene delivery: Recent advances and ongoing challenges, Ther. Deliv., 3, 1199, 10.4155/tde.12.100 · DOI
  53. Liang, 2010, Sonoporation, drug delivery, and gene therapy, Proc. Inst. Mech. Eng. Part H J. Eng. Med., 224, 343, 10.1243/09544119JEIM565 · DOI · Paper page
  54. Unger, 2001, Local drug and gene delivery through microbubbles, Prog. Cardiovasc. Dis., 44, 45, 10.1053/pcad.2001.26443 · DOI · Paper page
  55. Suda, 2007, Hydrodynamic gene delivery: Its principles and applications, Mol. Ther., 15, 2063, 10.1038/sj.mt.6300314 · DOI · Paper page
  56. Fabre, 2008, Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava, Gene Ther., 15, 452, 10.1038/sj.gt.3303079 · DOI
  57. Du, 2018, Advanced physical techniques for gene delivery based on membrane perforation, Drug Deliv., 25, 1516, 10.1080/10717544.2018.1480674 · DOI
  58. Zhang, 2010, Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles, ACS Nano, 4, 4733, 10.1021/nn9018812 · DOI
  59. Meacham, 2014, Physical methods for intracellular delivery: Practical aspects from laboratory use to industrial-scale processing, J. Lab. Autom., 19, 1, 10.1177/2211068213494388 · DOI · Paper page
  60. Li, 2008, Enhanced thoracic gene delivery by magnetic nanobead-mediated vector, J. Gene Med. A Cross-Discip. J. Res. Sci. Gene Transf. Its Clin. Appl., 10, 897
  61. Prosen, 2014, Mcam silencing with RNA interference using magnetofection has antitumor effect in murine melanoma, Mol. Ther.-Nucleic Acids, 3, e205, 10.1038/mtna.2014.56 · DOI
  62. Li, 2009, Nanoparticle delivery of anti-metastatic NM23-H1 gene improves chemotherapy in a mouse tumor model, Cancer Gene Ther., 16, 423, 10.1038/cgt.2008.97 · DOI
  63. Liu, 2002, Noninvasive gene delivery to the liver by mechanical massage, Hepatology, 35, 1314, 10.1053/jhep.2002.33467 · DOI
  64. Liu, 2004, Mechanism of liver gene transfer by mechanical massage, Mol. Ther., 9, 452, 10.1016/j.ymthe.2003.12.003 · doi:10.1016/j.ymthe.2003.12.003
  65. Wang, 2013, Non-viral gene delivery methods, Curr. Pharm. Biotechnol., 14, 46
  66. Khalid, 2017, Polymeric nanoparticles: Promising platform for drug delivery, Int. J. Pharm., 528, 675, 10.1016/j.ijpharm.2017.06.052 · DOI · Paper page
  67. Rose, 2017, Phosphonium polymers for gene delivery, Polym. Chem., 8, 353, 10.1039/C6PY01855F · DOI
  68. Nóbrega, C., Mendonça, L., and Matos, C.A. (2020). A Handbook of Gene and Cell Therapy, Springer. · DOI
  69. Park, 2006, Current status of polymeric gene delivery systems, Adv. Drug Deliv. Rev., 58, 467, 10.1016/j.addr.2006.03.007 · DOI · Paper page
  70. Schubert, 2012, Branched and linear poly (ethylene imine)-based conjugates: Synthetic modification, characterization, and application, Chem. Soc. Rev., 41, 4755, 10.1039/c2cs35146c · DOI · Paper page
  71. Liu, 2010, Hydrophobic modifications of cationic polymers for gene delivery, Prog. Polym. Sci., 35, 1144, 10.1016/j.progpolymsci.2010.04.007 · DOI · Paper page
  72. Cavalu, 2002, EPR study of non-covalent spin labeled serum albumin and hemoglobin, Biophys. Chem., 99, 181, 10.1016/S0301-4622(02)00182-5 · doi:10.1016/s0301-4622(02)00182-5
  73. Luten, 2008, Biodegradable polymers as non-viral carriers for plasmid DNA delivery, J. Control. Release, 126, 97, 10.1016/j.jconrel.2007.10.028 · DOI · Paper page
  74. Pashuck, 2012, Designing regenerative biomaterial therapies for the clinic, Sci. Transl. Med., 4, 160sr4, 10.1126/scitranslmed.3002717 · DOI · Paper page
  75. Vert, 2011, Degradable polymers in medicine: Updating strategies and terminology, Int. J. Artif. Organs, 34, 76, 10.5301/IJAO.2011.6400 · DOI
  76. Cavalu, S., Antoniac, I.V., Mohan, A., Bodog, F., Doicin, C., Mates, I., Ulmeanu, M., Murzac, R., and Semenescu, A. (2020). Nanoparticles and Nanostructured Surface Fabrication for Innovative Cranial and Maxillofacial Surgery. Materials, 13. · DOI
  77. Lee, 2013, Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice, J. Control. Release, 172, 358, 10.1016/j.jconrel.2013.09.002 · DOI
  78. Youngren, 2013, STAT6 siRNA matrix-loaded gelatin nanocarriers: Formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells, BioMed Res. Int., 2013, 858946, 10.1155/2013/858946 · DOI
  79. Syga, 2016, Albumin incorporation in polyethylenimine–DNA polyplexes influences transfection efficiency, Biomacromolecules, 17, 200, 10.1021/acs.biomac.5b01308 · DOI
  80. Hu, 2017, Versatile functionalization of polysaccharides via polymer grafts: From design to biomedical applications, Acc. Chem. Res., 50, 281, 10.1021/acs.accounts.6b00477 · DOI · Paper page
  81. Cavalu, 2018, Novel Formulation Based on Chitosan-Arabic Gum Nanoparticles Entrapping Propolis Extract Production, physico-chemical and structural characterization, Rev. Chim., 69, 3756, 10.37358/RC.18.12.6836 · DOI
  82. Kean, 2005, Trimethylated chitosans as non-viral gene delivery vectors: Cytotoxicity and transfection efficiency, J. Control. Release, 103, 643, 10.1016/j.jconrel.2005.01.001 · DOI · Paper page
  83. Lin, 2017, Hyaluronic acid conjugated micelles possessing CD44 targeting potential for gene delivery, Carbohydr. Polym., 155, 101, 10.1016/j.carbpol.2016.08.021 · DOI
  84. Liu, 2012, Synthesis, preparation, in vitro degradation, and application of novel degradable bioelastomers—A review, Prog. Polym. Sci., 37, 715, 10.1016/j.progpolymsci.2011.11.001 · DOI · Paper page
  85. Reul, 2009, Amine-modified hyperbranched polyesters as non-toxic, biodegradable gene delivery systems, Biomaterials, 30, 5815, 10.1016/j.biomaterials.2009.06.057 · DOI
  86. Liang, 2015, Optimizing the size of micellar nanoparticles for efficient siRNA delivery, Adv. Funct. Mater., 25, 4778, 10.1002/adfm.201501548 · DOI
  87. Liu, 2012, Therapeutic delivery of siRNA silencing HIF-1 α with micellar nanoparticles inhibits hypoxic tumor growth, Mol. Pharm., 9, 2863, 10.1021/mp300193f · DOI · Paper page
  88. Sun, 2011, Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression, ACS Nano, 5, 1483, 10.1021/nn103349h · DOI · Paper page
  89. Chen, 2014, Advanced drug and gene delivery systems based on functional biodegradable polycarbonates and copolymers, J. Control. Release, 190, 398, 10.1016/j.jconrel.2014.05.023 · DOI · Paper page
  90. Kawalec, 2015, Impact of the structure of biocompatible aliphatic polycarbonates on siRNA transfection ability, Biomacromolecules, 16, 769, 10.1021/bm501676p · DOI
  91. Yang, 2011, Novel biodegradable block copolymers of poly (ethylene glycol)(PEG) and cationic polycarbonate: Effects of PEG configuration on gene delivery, Macromol. Rapid Commun., 32, 1826, 10.1002/marc.201100350 · DOI
  92. Yang, 2012, Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI, Biomaterials, 33, 1462, 10.1016/j.biomaterials.2011.10.071 · DOI · Paper page
  93. Shin, 2020, COVID-19 vaccine development and a potential nanomaterial path forward, Nat. Nanotechnol., 15, 646, 10.1038/s41565-020-0737-y · DOI · Paper page
  94. Malabadi, 2021, Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (COVID-19), Int. J. Res. Sci. Innov., 8, 191
  95. Drummond, 2008, Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development, J. Pharm. Sci., 97, 4696, 10.1002/jps.21358 · DOI · Paper page
  96. Ewert, 2010, Cationic liposome–nucleic acid complexes for gene delivery and silencing: Pathways and mechanisms for plasmid DNA and siRNA, Nucleic Acid Transfection, 296, 191, 10.1007/128_2010_70 · DOI
  97. Felgner, 1987, Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. USA, 84, 7413, 10.1073/pnas.84.21.7413 · DOI · Paper page
  98. 2012, Targeted lipid-based systems for siRNA delivery, J. Drug Deliv. Sci. Technol., 22, 65, 10.1016/S1773-2247(12)50006-7 · DOI
  99. Karmali, 2007, Cationic liposomes as non-viral carriers of gene medicines: Resolved issues, open questions, and future promises, Med. Res. Rev., 27, 696, 10.1002/med.20090 · DOI · Paper page
  100. Siafaka, P.I., Üstündağ Okur, N., Karavas, E., and Bikiaris, D.N. (2016). Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: Current status and uses. Int. J. Mol. Sci., 17. · DOI · Paper page
  101. Moreira, 2010, Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment, Biotechnol. Bioeng., 107, 884, 10.1002/bit.22858 · DOI
  102. Kanamala, 2019, Dual pH-sensitive liposomes with low pH-triggered sheddable PEG for enhanced tumor-targeted drug delivery, Nanomedicine, 14, 1971, 10.2217/nnm-2018-0510 · DOI
  103. Zangabad, 2018, Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications, Nanotechnol. Rev., 7, 95, 10.1515/ntrev-2017-0154 · DOI · Paper page
  104. Dastidar, D.G., and Chakrabarti, G. (2019). Thermoresponsive drug delivery systems, characterization and application. Applications of Targeted Nano Drugs and Delivery Systems, Elsevier. · DOI
  105. Mollazadeh, 2021, Recent advances in the redox-responsive drug delivery nanoplatforms: A chemical structure and physical property perspective, Mater. Sci. Eng. C, 118, 111536, 10.1016/j.msec.2020.111536 · DOI · Paper page
  106. Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., and Kyzas, G.Z. (2020). Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers, 12. · DOI · Paper page
  107. Riley, M.K., and Vermerris, W. (2017). Recent advances in nanomaterials for gene delivery—a review. Nanomaterials, 7. · DOI · Paper page
  108. Peng, 2014, TAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells, Biomaterials, 35, 5605, 10.1016/j.biomaterials.2014.03.062 · DOI
  109. Kundu, 2017, Gold nanoparticles: Their application as antimicrobial agents and vehicles of gene delivery, Adv. Biotechnol. Microbiol., 4, 555
  110. Rezaei, 2021, A pseudohomogeneous nanocarrier based on carbon quantum dots decorated with arginine as an efficient gene delivery vehicle, Sci. Rep., 11, 13790, 10.1038/s41598-021-93153-4 · DOI
  111. Zhang, 2012, Quantum dot enabled molecular sensing and diagnostics, Theranostics, 2, 631, 10.7150/thno.4308 · DOI · Paper page
  112. Ramos-Perez, V., Cifuentes, A., Coronas, N., de Pablo, A., and Borrós, S. (2013). Modification of carbon nanotubes for gene delivery vectors. Nanomaterial Interfaces in Biology, Springer. · doi:10.1007/978-1-62703-462-3_20
  113. Mebert, 2017, Nanoengineered silica: Properties, applications and toxicity, Food Chem. Toxicol., 109, 753, 10.1016/j.fct.2017.05.054 · DOI · Paper page
  114. Cavalu, 2013, Microscopic and spectroscopic investigation of bioactive glasses for antibiotic controlled release, J. Mol. Struct., 1040, 47, 10.1016/j.molstruc.2013.02.016 · DOI
  115. Huang, 2010, The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species, Biomaterials, 31, 6142, 10.1016/j.biomaterials.2010.04.055 · DOI

Cited by

Metadata

Authors
Butt, M., Zaman, M., Ahmad, A., Khan, R., Mallhi, T., Hasan, M., Khan, Y., Hafeez, S., Massoud, E., Rahman, M., & Cavalu, S.
Venue
Genes
Publisher
MDPI AG
Published
2022-07-30
Volume
13
Issue
8
Pages
1370
ISSN
2073-4425 (ISSN-L)
OpenAlex
W4289133916
Cited by
210
References
21
FWCI
12.29
Type
journal article
Language
en
Open access
gold
Funders
Deanship of Scientific Research at King Khalid University, Abha, Saudi Arabia (No. R.G.P.2/7/43)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.